ANN ARBOR, MI--(Marketwire - January 07, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP) ("Pipex"), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced that it has initiated a 150-patient, double-blind, placebo-controlled Phase II clinical trial of its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate) for the treatment of Alzheimer's disease (AD). The clinical trial is being led by the leading clinical research group that first discovered and has most extensively studied and published findings of elevated toxic free copper levels in the serum of Alzheimer's patients. The Phase II clinical trial is also being partially supported by a grant from Italian Ministry of Health which is expected to fund approximately 30% of the cost of the trial.
